{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:46:24Z","timestamp":1793407584950,"version":"4.5.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Livedoid vasculopathy is a rare, chronic-recurrent occlusive disorder in the microcirculation of dermal vessels. The clinical appearance is characterized by <jats:italic>Livedo racemosa<\/jats:italic>, painful ulceration, located in the distal parts of the lower extremities, followed by healing as porcelain-white, atrophic scars, the so-called <jats:italic>Atrophie blanche<\/jats:italic>. Different conditions that can promote a hypercoagulable state, such as inherited and acquired thrombophilias, autoimmune connective-tissue diseases and neoplasms, can be associated with livedoid vasculopathy. Therefore, livedoid vasculopathy is currently considered to be a coagulation disorder, clearly distinguished from inflammatory vasculitis. Although there are hints to hypercoaguability and secondary inflammation, pathophysiology is not completely understood. Diagnosis is made by synopsis of history, clinical and histopathological findings. Early and adequate therapy is essential to maintain life quality and avoid irreversible complications. Better understanding of molecular mechanisms is required to establish appropriate therapy regimens. This article presents the current state of knowledge about livedoid vasculopathy and proposes an algorithmic approach for diagnosis and therapy.<\/jats:p>","DOI":"10.3389\/fmed.2022.1012178","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T09:56:12Z","timestamp":1664790972000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Livedoid vasculopathy \u2013 A diagnostic and therapeutic challenge"],"prefix":"10.3389","volume":"9","author":[{"given":"Maria Rosa","family":"Burg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Mitschang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Goerge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan Werner","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.autrev.2010.11.008","article-title":"Livedoid vasculopathy as a coagulation disorder.","volume":"10","author":"Criado","year":"2011","journal-title":"Autoimmun Rev."},{"key":"B2","first-page":"865","article-title":"Les Atrophies Cutan\u00e8es Syphilitiques","volume":"36","author":"Milian","year":"1929","journal-title":"Bull Soc Franc Derm Syph"},{"key":"B3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/archderm.134.4.491","article-title":"Livedoid vasculopathy: what is it?","volume":"134","author":"Jorizzo","year":"1998","journal-title":"Arch Dermatol."},{"key":"B4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archderm.1983.01650360009005","article-title":"Classification and therapy of atrophie blanche.","volume":"119","author":"Milstone","year":"1983","journal-title":"Arch Dermatol."},{"key":"B5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/archderm.1967.01610050011002","article-title":"Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis.","volume":"96","author":"Bard","year":"1967","journal-title":"Arch Dermatol."},{"key":"B6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/archderm.1971.04000210028005","article-title":"Immunofluorescence of cutaneous vasculitis associated with systemic disease.","volume":"104","author":"Schroeter","year":"1971","journal-title":"Arch Dermatol."},{"key":"B7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2230.1992.tb02522.x","article-title":"Livedo vasculitis: vasculitis or thrombotic vasculopathy?","volume":"17","author":"McCalmont","year":"1992","journal-title":"Clin Exp Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/DAD.0b013e3181b7bf90","article-title":"Distinct pattern of direct immunofluorescence in livedoid vasculopathy.","volume":"32","author":"Hsiao","year":"2010","journal-title":"Am J Dermatopathol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaad.2014.06.030","article-title":"Quality-of-life impairment in patients with livedoid vasculopathy.","volume":"71","author":"Polo Gascon","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1016\/S2352-3026(15)00251-3","article-title":"Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.","volume":"3","author":"Weishaupt","year":"2016","journal-title":"Lancet Haematol."},{"key":"B11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1111\/jdv.14190","article-title":"Analysis of the German DRG data for livedoid vasculopathy and calciphylaxis.","volume":"31","author":"Renner","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1111\/jdv.15639","article-title":"Characteristics, risk factors and treatment reality in livedoid vasculopathy \u2013 a multicentre analysis.","volume":"33","author":"Weishaupt","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.4103\/0378-6323.183635","article-title":"Livedoid vasculopathy: a review of pathogenesis and principles of management.","volume":"82","author":"Vasudevan","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/archderm.142.11.1413","article-title":"Livedoid vasculopathy: further evidence for procoagulant pathogenesis.","volume":"142","author":"Hairston","year":"2006","journal-title":"Arch Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2340\/00015555-2965","article-title":"Livedoid vasculopathy: a french observational study including therapeutic options.","volume":"98","author":"Gardette","year":"2018","journal-title":"Acta Derm Venereol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14810","article-title":"Livedoid vasculopathy in 75 Brazilian patients in a single-center institution: clinical, histopathological and therapy evaluation.","volume":"34","author":"Criado","year":"2021","journal-title":"Dermatol Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2340\/00015555-1711","article-title":"Livedoid vasculopathy: clinical features and treatment in 24 Chinese patients.","volume":"94","author":"Feng","year":"2014","journal-title":"Acta Derm Venereol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/archderm.134.4.447","article-title":"Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies.","volume":"134","author":"Papi","year":"1998","journal-title":"Arch Dermatol."},{"key":"B20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jaad.2013.01.043","article-title":"The skin and hypercoagulable states.","volume":"69","author":"Thornsberry","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ijwd.2021.08.013","article-title":"Livedoid vasculopathy: a multidisciplinary clinical approach to diagnosis and management.","volume":"7","author":"Bilgic","year":"2021","journal-title":"Int J Womens Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00105-011-2172-3","article-title":"[Livedoid vasculopathy. Pathogenesis, diagnosis and treatment of cutaneous infarction].","volume":"62","author":"Goerge","year":"2011","journal-title":"Hautarzt."},{"key":"B23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2133.1973.tb07539.x","article-title":"Observations on tissue fibrinolytic activity in patients with cutaneous vasculitis.","volume":"88","author":"Dodman","year":"1973","journal-title":"Br J Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/iwj.13563","article-title":"Livedoid vasculopathy and its association with genetic variants: a systematic review.","volume":"18","author":"Gao","year":"2021","journal-title":"Int Wound J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.mehy.2015.08.009","article-title":"Lipoprotein(a) and livedoid vasculopathy: a new thrombophilic factor?","volume":"85","author":"Criado","year":"2015","journal-title":"Med Hypotheses."},{"key":"B26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/dth.12225","article-title":"Livedoid vasculopathy and high levels of lipoprotein (a): response to danazol.","volume":"28","author":"Criado","year":"2015","journal-title":"Dermatol Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/cup.13043","article-title":"Analysis of serum levels and cutaneous expression of lipoprotein (a) in 38 patients with livedoid vasculopathy.","volume":"44","author":"Espinel","year":"2017","journal-title":"J Cutan Pathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/j.1468-3083.2010.03646.x","article-title":"Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs \u2013 a prospective study.","volume":"24","author":"Di Giacomo","year":"2010","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1111\/jdv.16129","article-title":"Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment.","volume":"34","author":"Lee","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1111\/jdv.17613","article-title":"Real-world data on pain management and effectiveness of anti-tumour necrosis factor agents in refractory livedoid vasculopathy.","volume":"36","author":"Gao","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaad.2013.07.019","article-title":"Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach.","volume":"69","author":"Alavi","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14565","article-title":"From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy.","volume":"34","author":"Criado","year":"2021","journal-title":"Dermatol Ther."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6644853","article-title":"Cutaneous vasculopathy in a COVID-19 critically ill patient: a histologic, immunohistochemical, and electron microscopy study.","volume":"2021","author":"Kyriakoudi","year":"2021","journal-title":"Case Rep Crit Care."},{"key":"B34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/DAD.0000000000000766","article-title":"Occlusive nonvasculitic vasculopathy.","volume":"39","author":"Llamas-Velasco","year":"2017","journal-title":"Am J Dermatopathol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jdcr.2022.03.025","article-title":"The clot thickens with COVID-19 and cryofibrinogenemia: a thought-provoking association.","volume":"24","author":"Perry","year":"2022","journal-title":"JAAD Case Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1111\/ijd.15423","article-title":"Recrudescence of livedoid vasculopathy induced by COVID-19.","volume":"60","author":"Valentim","year":"2021","journal-title":"Int J Dermatol."},{"key":"B37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1684\/ejd.2022.4200","article-title":"Exacerbation of livedoid vasculopathy after coronavirus disease 2019.","volume":"32","author":"Kawabe","year":"2022","journal-title":"Eur J Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/ddg.14520","article-title":"German S1 guideline: diagnosis and treatment of livedovasculopathy.","volume":"19","author":"Schiffmann","year":"2021","journal-title":"J Dtsch Dermatol Ges."},{"key":"B39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1590\/s0365-05962011000500015","article-title":"Livedoid vasculopathy: an intringuing cutaneous disease.","volume":"86","author":"Criado","year":"2011","journal-title":"An Bras Dermatol."},{"key":"B40","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archderm.1975.01630140046003","article-title":"Livedo vasculitis (the vasculitis of atrophie blanche). Immunohistopathologic study.","volume":"111","author":"Schroeter","year":"1975","journal-title":"Arch Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/ced.12157","article-title":"Direct immunofluorescence findings and thrombophilic factors in livedoid vasculopathy: How do they correlate?","volume":"39","author":"Criado","year":"2014","journal-title":"Clin Exp Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/ced.14464","article-title":"Direct immunofluorescence findings in livedoid vasculopathy: a 10-year study and literature review.","volume":"46","author":"Nuttawong","year":"2021","journal-title":"Clin Exp Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1534734619896938","article-title":"Livedo racemosa: clinical, laboratory, and histopathological findings in 33 patients.","volume":"20","author":"Pincelli","year":"2021","journal-title":"Int J Low Extrem Wounds."},{"key":"B44","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jaad.2019.07.113","article-title":"Retiform purpura: workup and therapeutic considerations in select conditions.","volume":"82","author":"Georgesen","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B45","article-title":"Dermoscopic features of livedoid vasculopathy.","volume":"96","author":"Hu","year":"2017","journal-title":"Medicine."},{"key":"B46","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/CM9.0000000000001048","article-title":"Clinical and dermoscopic features of livedoid vasculopathy.","volume":"133","author":"Wen","year":"2020","journal-title":"Chin Med J."},{"key":"B47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archderm.1955.03730310033007","article-title":"Livedo reticularis with summer ulcerations.","volume":"72","author":"Feldaker","year":"1955","journal-title":"AMA Arch Derm."},{"key":"B48","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1024\/0301-1526\/a000296","article-title":"Livedoid vasculopathy \u2013 a thrombotic disease.","volume":"42","author":"Kerk","year":"2013","journal-title":"VASA."},{"key":"B49","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/nan.12243","article-title":"Expanding the spectrum of livedoid vasculopathy: peculiar neuromuscular manifestations.","volume":"41","author":"Allenbach","year":"2015","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B50","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1007\/s00415-022-11007-z","article-title":"Peripheral neuropathy and livedoid vasculopathy.","volume":"269","author":"Soulages","year":"2022","journal-title":"J Neurol."},{"key":"B51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-4362.1999.00581.x","article-title":"Atrophie blanche.","volume":"38","author":"Maessen-Visch","year":"1999","journal-title":"Int J Dermatol."},{"key":"B52","first-page":"237","article-title":"Atrophie blanche. a clinicopathological study of 27 patients.","volume":"14","author":"Yang","year":"1991","journal-title":"Changgeng Yi Xue Za Zhi."},{"key":"B53","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1046\/j.1365-2133.2003.05176.x","article-title":"Cutaneous polyarteritis nodosa in patients presenting with atrophie blanche.","volume":"148","author":"Mimouni","year":"2003","journal-title":"Br J Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jaad.2021.03.108","article-title":"In vitro diagnostics for the medical dermatologist. Part II: Hypercoagulability tests.","volume":"85","author":"Nusbaum","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2492","article-title":"Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis.","volume":"346","author":"Schouten","year":"2013","journal-title":"BMJ."},{"key":"B56","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/01.ASW.0000455098.98684.95","article-title":"Atrophie blanche: is it associated with venous disease or livedoid vasculopathy?","volume":"27","author":"Alavi","year":"2014","journal-title":"Adv Skin Wound Care."},{"key":"B57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jamadermatol.2017.4374","article-title":"Treatment for livedoid vasculopathy: a systematic review.","volume":"154","author":"Micieli","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1001\/archderm.139.8.987","article-title":"Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases.","volume":"139","author":"Hairston","year":"2003","journal-title":"Arch Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/archdermatol.2010.177","article-title":"Livedoid vasculopathy in a pediatric patient with elevated lipoprotein(a) levels: prompt response to continuous low-molecular-weight heparin.","volume":"146","author":"Goerge","year":"2010","journal-title":"Arch Dermatol."},{"key":"B60","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15051","article-title":"Rivaroxaban for treatment of livedoid vasculopathy: a systematic review.","volume":"34","author":"Gao","year":"2021","journal-title":"Dermatol Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/archderm.142.11.1481","article-title":"Livedoid vasculopathy: what it is and how the patient should be evaluated and treated.","volume":"142","author":"Callen","year":"2006","journal-title":"Arch Dermatol."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13229","article-title":"Intravenous immunoglobulin in resistant livedoid vasculopathy: analysis of a case series.","volume":"33","author":"Ozden","year":"2020","journal-title":"Dermatol Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1177\/12034754211003525","article-title":"Intravenous immunoglobulin therapy in livedoid vasculopathy: retrospective observation of clinical outcome and patient\u2019s activity level.","volume":"25","author":"Kofler","year":"2021","journal-title":"J Cutan Med Surg."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/j.1365-4632.2012.05826.x","article-title":"Intravenous immunoglobulins in difficult-to-treat ulcerated livedoid vasculopathy: five cases and a literature review.","volume":"52","author":"Bounfour","year":"2013","journal-title":"Int J Dermatol."},{"key":"B65","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jaad.2014.05.039","article-title":"Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients.","volume":"71","author":"Monshi","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/dth.12233","article-title":"Pulsed intravenous immunoglobulin therapy in refractory ulcerated livedoid vasculopathy: seven cases and a literature review.","volume":"28","author":"Kim","year":"2015","journal-title":"Dermatol Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/09546634.2020.1737634","article-title":"Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.","volume":"33","author":"Gao","year":"2022","journal-title":"J Dermatolog Treat."},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10040549","article-title":"Adalimumab in treating refractory livedoid vasculopathy.","volume":"10","author":"Huang","year":"2022","journal-title":"Vaccines."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14470","article-title":"Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.","volume":"33","author":"Jia","year":"2020","journal-title":"Dermatol Ther."},{"key":"B70","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamadermatol.2022.0241","article-title":"Treatment of livedoid vasculopathy with baricitinib.","volume":"158","author":"Song","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.3640","article-title":"Phase II multicenter trial with rivaroxaban in the treatment of livedoid vasculopathy assessing pain on a visual analog scale.","volume":"3","author":"Drabik","year":"2014","journal-title":"JMIR Res Protoc."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1012178\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T09:56:37Z","timestamp":1664790997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1012178\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":72,"alternative-id":["10.3389\/fmed.2022.1012178"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1012178","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"article-number":"1012178"}}